ConCallIQ
Go Pro
ADVANCEDENZYMETECHNOLOGI Healthcare 2026-04-??

Advanced Enzyme Technologies Ltd — Q4 FY26

Advanced Enzyme delivered a record quarter with revenue of ₹203.4 crore (+22% YoY) and EBITDA of ₹63.2 crore (+39% YoY), driven by strong volume growth in human healthcare (up 2...

bullish high
Compare with...
Revenue ₹203 Cr +22%
EBITDA ₹63 Cr +39%
PAT ₹45 Cr +69%
EBITDA Margin 31%
Duration 84 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

US tariff and inflation impact

US business faces 18% tariff and rising inflation, pressuring margins and demand. Management is absorbing ~10% cost increase.

high · management_commentary
R

Gross margin pressure from product mix

Analyst noted sequential gross margin decline; management attributed to product mix and higher domestic sales, which carry lower margins.

medium · analyst_question
R

Key management departure

Mr. Deepak Lala, a long-time executive, has left. Management stated roles are split between two heads, but transition risk remains.

medium · analyst_question
R

Geopolitical supply chain disruptions

Conflicts and trade restrictions could escalate input costs (fuel, solvents, packaging) and logistics, impacting margins.

medium · management_commentary